About Cergentis
Cergentis is a company based in Utrecht (Netherlands) founded in 2012 was acquired by Solvias in July 2022. Cergentis offers products and services including Targeted Locus Amplification (TLA). Cergentis operates in a competitive market with competitors including RareCyte, Sequenta, seqWell, Paragon Genomics and Neogen, among others.
- Headquarter Utrecht, Netherlands
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Bangalore North, Karnataka, India
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cergentis
Cergentis offers a comprehensive portfolio of products and services, including Targeted Locus Amplification (TLA).
Platform for genetic characterization and QC in advanced therapies.
People of Cergentis
Unlock access to complete
Unlock access to complete
Funding Insights of Cergentis
Investors in Cergentis
Cergentis has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Solvias, European Union and EIC Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Integrated R&D services are provided for pharmaceuticals and allied sectors.
|
Locked | Locked | Locked |
Investor details for Cergentis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cergentis
Investment portfolio details for Cergentis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cergentis
Detailed financials for Cergentis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cergentis Comparisons
Peer comparison for Cergentis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cergentis
Cergentis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as RareCyte, Sequenta, seqWell, Paragon Genomics and Neogen, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of technologies for the analysis of rare and single cells in the blood
|
|
| Locked | Locked | Locked |
Immuno-sequencing products are developed for disease diagnostics and treatment.
|
|
| Locked | Locked | Locked |
NGS-based reagents and kits are supplied for life sciences research.
|
|
| Locked | Locked | Locked |
Provider of technologies and solutions genomic research and precision medicine
|
|
| Locked | Locked | Locked |
Manufacturer of products in the areas of veterinary diagnostics, life sciences, DNA testing, and drug testing
|
|
| Locked | Locked | Locked |
Molecular biology reagents and services are supplied to biotech industries.
|
Detailed competitors of Cergentis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cergentis
Complete news archive for Cergentis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cergentis
Cergentis was founded in 2012 and raised its 1st funding round 6 years after it was founded.
Cergentis is headquartered in Utrecht, Netherlands.
Annual revenue of Cergentis is $403.09K as on Mar 31, 2022.
Cergentis was founded in 2012 and is based in Utrecht, Netherlands. Targeted sequencing kits and services are offered in the genomics sector. The proprietary Targeted Locus Amplification (TLA) technology is employed to achieve complete next-generation sequencing of genomic loci through a single primer pair, amplifying thousands of base pairs. Applications encompass oncogenetics, transgene integration site analysis, full gene sequencing, genetic diagnostics, and agricultural genomics.
Cergentis's top competitors include Neogen, Paragon Genomics and Biotangents.
Cergentis offers Targeted Locus Amplification (TLA).
Cergentis has 3 investors. Key investors include Solvias, European Union, and EIC Fund.